The Fox Chase Chemical Diversity Center, Inc. (FCCDC)

 

The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase I STTR Entitled “Development of Small Molecule Therapeutics Against RNA Viruses”

 

Doylestown, PA. January 23, 2015- FCCDC is pleased to announce that it has been awarded a Phase I STTR entitled “Development of Small Molecule Therapeutics Against RNA Viruses” (1R41AI113952-01A1). The principal investigator is Prof. Ronald N. Harty of the University of Pennsylvania.